30 Day Trial

Seikagaku Reports FY 2Q18 Revenue of ¥7,030, -12% vs. FY 2Q17


Seikagaku continues slide caused by drug price reductions, posts FY 2Q18 revenue of ¥7,030 (USD $66MM), -12% vs. FY 2Q17.

This article is a Member-only item of content. Members, please log in to read the complete post.
If you are not yet a Member, click here to learn more about purchasing ORTHOWORLD Membership.